Latest News

Big multiple sclerosis breakthrough: Phase 1 trial safely resets patients' immune systems and reduces attack on myelin protein

A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients' immune systems' reactivity to myelin by 50 to 75 percent. The therapy used billions of patients' own specially processed blood cells to create tolerance to myelin, the insulating layer that forms around nerves. In MS, the immune system attacks myelin. The approach left the normal immune system intact.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • New gadget helps vision-impaired to read graphs

  • Problem drinking in midlife doubles chance of memory problems in later life

  • Teen insomnia linked with depression, anxiety

  • Brain response to appetizing food cues varies among obese people

  • Parenting skills improve in ADHD parents with medication

  • Numerical learning disability: Dyscalculia linked to difficulties in reading and spelling

  • Sugar mimics guide stem cells toward neural fate

  • Laughter is the best medicine? The emotional appeal of stand-up comedy

  • Many depressed preschoolers still suffer in later school years

  • Naltrexone may be effective in diminishing impulse control disorders in Parkinson's disease patients

  •